Showing Results for: “diabetes”

The American Diabetes Association ® (ADA) welcomes the 2025 principal officers and board of directors. The 15-member board comprises forward-thinking and innovative medical, scientific, education, and executive business professionals who will strategically lead and focus efforts to ensure the ADA continues to advance the mission upon which it was founded. "We are so excited to announce our 2025 board of directors,” said Charles “Chuck” Henderson, the ADA’s chief executive officer. “We look forward to the insight and skills each of these thought leaders will provide to help move the needle and

Yesterday, Maryland Governor Lawrence (Larry) Hogan, Jr. signed Senate Bill 353 and House Bill 1397 – a critical action that will help save lives and reduce the burden of insulin costs for people living with diabetes in Maryland. The American Diabetes Association® (ADA) applauds Governor Hogan for signing the legislation that will cap copayments for insulin at $30 per 30-day supply for those on state-regulated commercial health insurance plans. Improving insulin affordability helps people with diabetes to manage the disease, stay healthy, and reduce their risk for dangerous complications

The American Diabetes Association® (ADA) welcomes the 2026 principal officers and board of directors. The 15-member board comprises forward-thinking and innovative medical, scientific, education, and executive business professionals who will strategically lead and focus efforts to ensure the ADA continues to advance the mission upon which it was founded. "We are thrilled to welcome our 2026 board of directors,” said Charles “Chuck” Henderson, the ADA’s chief executive officer. “We look forward to the contributions of these talented and knowledgeable leaders as we fight for a world free of

The U.S. Food and Drug Administration (FDA) convened the Endocrinologic and Metabolic Drugs Advisory Committee Meeting (EMDAC) on May 27, 2021, to review Teplizumab, which has shown the ability to delay the onset of Type 1 diabetes symptoms by two years. The American Diabetes Association ® (ADA) applauds the FDA Advisory Committee’s approval of Teplizumab for those at risk for developing type 1 diabetes (T1D). Click here to view the official comments submitted by the ADA. In response, Dr. Robert Gabbay, Chief Scientific and Medical Officer for the ADA shared the following: “This is undoubtedly

Today, the U.S. Food & Drug Administration (FDA) officially moved insulin to the biologic regulatory framework. All insulins on the market have officially been deemed biologics by the FDA—paving the way for biosimilar and interchangeable insulins. Learn more about what this change means for people living with diabetes at diabetes.org/biologics. LaShawn McIver, MD, MPH, Senior Vice President of Government Affairs & Advocacy for the American Diabetes Association (ADA), issued the following statement: "Insulin is life-sustaining for about seven million Americans—too many of whom can’t afford it

The American Diabetes Association ® (ADA) welcomes the 2024 principal officers and board of directors. The 15-member board is comprised of forward-thinking and innovative medical, scientific, education, and executive business professionals who will strategically lead and focus efforts to ensure the ADA continues to advance the mission upon which it was founded. "We are so excited to announce our 2024 board of directors,” said Charles “Chuck” Henderson, the ADA’s chief executive officer. “We look forward to the insight and skills each of these thought leaders will provide to help move the

This week, the Centers for Medicare & Medicaid Services (CMS) released an interim final rule implementing the new community engagement requirements for Medicaid beneficiaries included in healthcare and tax legislation Congress passed last summer. Beginning January 1, 2027, with some exceptions, individuals enrolled in Medicaid must work, volunteer, or participate in job training for at least 80 hours per month to maintain coverage. In response the American Diabetes Association® (ADA) issued the following statement. The ADA is very concerned about the forthcoming impact of new Medicaid work

As part of the Biden administration’s plan to review Trump executive actions on health care, the U.S. Department of Health and Human Services (HHS) announced a delay in implementation of the “rebate rule,” moving the effective date from January 1, 2022, to January 1, 2023. The Trump administration announced its rebate proposal in 2018. The proposed rule would have effectively banned the rebates drug manufacturers give to pharmacy benefit managers in Medicare Part D—Medicare’s prescription drug program—only allowing rebates at the point of sale in an effort to reduce patients’ out-of-pocket

The ADA will work with AWS to revamp their data architecture to enable the advancement of the ADA’s mission Today, the American Diabetes Association® (ADA) announced it has been selected as a winner of the 2024 Amazon Web Services (AWS) IMAGINE Grant, a public grant opportunity open to registered charities in the United Kingdom and Ireland and registered 501(c) nonprofit organizations in the United States who are using technology to solve the world’s most pressing challenges. The grant will support the ADA's efforts to revamp its data architecture to boost donation revenue which will enable

The American Diabetes Association® (ADA) will present the 2019 Banting Medal for Scientific Achievement, the ADA’s highest honor, to Stephen O’Rahilly, MD. The Banting Medal recognizes significant, long-term contributions to the understanding, treatment or prevention of diabetes. Dr. O’Rahilly will be recognized with this honor during the ADA’s 79th Scientific Sessions, June 7-11, 2019, at the Moscone Convention Center in San Francisco, and will deliver his Banting Medal Lecture, titled “ Treasure Your Exceptions—Studying Human Extreme Phenotypes to Illuminate Metabolic Health and Disease,”